Drug Information

Drug (ID: DG01636) and It's Reported Resistant Information

Name	E7090
Synonyms	E-7090; E7090; 1622204-21-0; tasurgratinib; TN7CUD1NGA; UNII-TN7CUD1NGA; 5-((2-(4-(1-(2-hydroxyethyl)piperidin-4-yl)benzamido)pyridin-4-yl)oxy)-6-(2-methoxyethoxy)-N-methyl-1H-indole-1-carboxamide; 5-[2-[[4-[1-(2-hydroxyethyl)piperidin-4-yl]benzoyl]amino]pyridin-4-yl]oxy-6-(2-methoxyethoxy)-N-methylindole-1-carboxamide; CHEMBL3686884; SCHEMBL15955142; GTPL11414; BDBM142256; Fgf/fgfr pathway inhibitor E7090; BCP29727; EX-A2908; NSC806388; NSC-806388; SB18854; Example 22 [WO2014129477A1]; HY-101466; CS-0021430; E 7090; E7090; US8933099, 22; Q27896113; 1H-Indole-1-carboxamide, 5-((2-((4-(1-(2-hydroxyethyl)-4-piperidinyl)benzoyl)amino)-4-pyridinyl)oxy)-6-(2-methoxyethoxy)-N-methyl-; 5-((2-(((4-(1-(2-Hydroxyethyl)piperidin-4-yl)phenyl)carbonyl)amino)pyridin-4-yl)oxy)-6-(2-methoxyethoxy)-N-methyl-1H-indole-1-carboxamide Click to Show/Hide
Structure
Target	.	NOUNIPROTAC	[1]
Click to Show/Hide the Molecular Information and External Link(s) of This Drug
Formula	11
IsoSMILES	CNC(=O)N1C=CC2=CC(=C(C=C21)OCCOC)OC3=CC(=NC=C3)NC(=O)C4=CC=C(C=C4)C5CCN(CC5)CCO
InChI	InChI=1S/C32H37N5O6/c1-33-32(40)37-14-10-25-19-29(28(21-27(25)37)42-18-17-41-2)43-26-7-11-34-30(20-26)35-31(39)24-5-3-22(4-6-24)23-8-12-36(13-9-23)15-16-38/h3-7,10-11,14,19-21,23,38H,8-9,12-13,15-18H2,1-2H3,(H,33,40)(H,34,35,39)
InChIKey	IBHOLSBDZMIPPT-UHFFFAOYSA-N
PubChem CID	78323434

Type(s) of Resistant Mechanism of This Drug

ADTT: Aberration of the Drug's Therapeutic Target

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-02: Benign/in-situ/malignant neoplasm

Click to Show/Hide the Resistance Disease of This Class

Multiple myeloma [ICD-11: 2A83]

Click to Show/Hide

Drug Sensitivity Data Categorized by Their Corresponding Mechanisms
Aberration of the Drug's Therapeutic Target (ADTT)		Click to Show/Hide
Key Molecule: Fibroblast growth factor receptor 3 (FGFR3)			[1]
Molecule Alteration	Missense mutation	p.Y373C (c.1118A>G)	Molecule Info
Sensitive Disease	Multiple myeloma [ICD-11: 2A83.0]		Disease Info
Experimental Note	Identified from the Human Clinical Data

Endometrial cancer [ICD-11: 2C76]

Click to Show/Hide

Drug Sensitivity Data Categorized by Their Corresponding Mechanisms
Aberration of the Drug's Therapeutic Target (ADTT)		Click to Show/Hide
Key Molecule: Fibroblast growth factor receptor 2 (FGFR2)			[1]
Molecule Alteration	Missense mutation	p.S252W (c.755C>G)	Molecule Info
Sensitive Disease	Endometrial adenocarcinoma [ICD-11: 2C76.0]		Disease Info
Experimental Note	Identified from the Human Clinical Data

References

Ref 1	E7090, a Novel Selective Inhibitor of Fibroblast Growth Factor Receptors, Displays Potent Antitumor Activity and Prolongs Survival in Preclinical ModelsMol Cancer Ther. 2016 Nov;15(11):2630-2639. doi: 10.1158/1535-7163.MCT-16-0261. Epub 2016 Aug 17.